Regeneron price target lowered to $759 from $940 at Baird
Baird lowered the firm’s price target on Regeneron (REGN) to $759 from $940 and keeps a Neutral rating on the shares. The firms lower target ...
Regeneron upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...
Regeneron Beats Quarterly Estimates on Eczema Drug Demand; Launches Dividend Program
(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...
GitHub2d
Tabler Icons
A set of 5844 free MIT-licensed high-quality SVG icons for you to use in your web projects. Each icon is designed on a 24x24 grid and a 2px stroke. If you load an icon as an image, you can modify its ...
Sanofi Plans Share Buybacks, Signals More Deals Post Opella Sale
The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the ...